Nothing Special   »   [go: up one dir, main page]

PE20190209A1 - Anticuerpos anti-factor bb del complemento y uso de estos - Google Patents

Anticuerpos anti-factor bb del complemento y uso de estos

Info

Publication number
PE20190209A1
PE20190209A1 PE2018001946A PE2018001946A PE20190209A1 PE 20190209 A1 PE20190209 A1 PE 20190209A1 PE 2018001946 A PE2018001946 A PE 2018001946A PE 2018001946 A PE2018001946 A PE 2018001946A PE 20190209 A1 PE20190209 A1 PE 20190209A1
Authority
PE
Peru
Prior art keywords
antibodies
factor
complement
seq
complement anti
Prior art date
Application number
PE2018001946A
Other languages
English (en)
Inventor
Sandip Panicker
Graham Parry
Karen Christopherson
Tony Sang Young Byun
Original Assignee
Bioverativ Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioverativ Usa Inc filed Critical Bioverativ Usa Inc
Publication of PE20190209A1 publication Critical patent/PE20190209A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LSe refiere a un anticuerpo especifico para el factor Bb del complemento, comprende CDRs de cadena ligera como SEQ ID NO: 7,15, 23, 31, 39, 47 y CDRs de cadena pesada como SEQ ID NO: 8, 16, 24, 32, 40 y 48. Los anticuerpos anti-Bb son utiles para el tratamiento de trastornos mediados por el complemento.
PE2018001946A 2016-04-04 2017-04-03 Anticuerpos anti-factor bb del complemento y uso de estos PE20190209A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662317897P 2016-04-04 2016-04-04
PCT/US2017/025784 WO2017176651A1 (en) 2016-04-04 2017-04-03 Anti-complement factor bb antibodies and uses thereof

Publications (1)

Publication Number Publication Date
PE20190209A1 true PE20190209A1 (es) 2019-02-07

Family

ID=60000646

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018001946A PE20190209A1 (es) 2016-04-04 2017-04-03 Anticuerpos anti-factor bb del complemento y uso de estos

Country Status (23)

Country Link
US (3) US10934347B2 (es)
EP (1) EP3452510A4 (es)
JP (3) JP6967528B2 (es)
KR (2) KR20240096672A (es)
CN (2) CN116790614A (es)
AU (2) AU2017246794B2 (es)
BR (1) BR112018070357A2 (es)
CA (1) CA3019332A1 (es)
CL (1) CL2018002810A1 (es)
CO (1) CO2018010827A2 (es)
CR (1) CR20180529A (es)
DO (1) DOP2018000219A (es)
EA (1) EA201892225A1 (es)
EC (1) ECSP18082302A (es)
IL (3) IL262010B (es)
MA (1) MA44878A (es)
MX (2) MX2018012176A (es)
MY (1) MY194603A (es)
PE (1) PE20190209A1 (es)
PH (1) PH12018502137A1 (es)
SG (1) SG11201808525UA (es)
TN (1) TN2018000341A1 (es)
WO (1) WO2017176651A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR082404A1 (es) 2010-07-28 2012-12-05 Gliknik Inc Proteinas de fusion de fragmentos de proteinas humanas naturales para crear composiciones de inmunoglobulinas fc ordenadamente multimerizadas
KR102649702B1 (ko) 2015-07-24 2024-03-21 글리크닉 인코포레이티드 향상된 상보체 결합을 갖는 규칙적으로 다형체화된 면역글로불린 fc 조성물을 생성하기 위한 인간 단백질 단편의 융합 단백질
SG11201808525UA (en) 2016-04-04 2018-10-30 Bioverativ Usa Inc Anti-complement factor bb antibodies and uses thereof
CA3043251A1 (en) 2016-12-09 2018-06-14 Gliknik Inc. Methods of treating inflammatory disorders with multivalent fc compounds
IL266936B1 (en) 2016-12-09 2024-12-01 Gliknik Inc Manufacturing Optimization of GL-2045, a Multimerizing Stradomer, compositions and uses thereof
US11690919B2 (en) * 2017-01-17 2023-07-04 The Texas A&M University System Endolysosomal targeting conjugates for improved delivery of cargo molecules to the endolysosomal compartment of target cells
EP3694874A1 (en) * 2017-10-11 2020-08-19 Bioverativ USA Inc. Methods of inducing complement activity
EP3728568A4 (en) 2017-12-19 2021-10-06 The University of North Carolina at Chapel Hill METHODS AND COMPOSITIONS FOR THE ADMINISTRATION OF VIRAL VECTORS ACROSS THE HAEMATOENCEPHALIC BARRIER
CA3142840A1 (en) * 2019-06-27 2020-12-30 Verseau Therapeutics, Inc. Anti-cd53 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
US11820814B2 (en) * 2019-07-17 2023-11-21 Gemini Therapeutics Sub, Inc. Factor H potentiating antibodies and uses thereof
WO2021167949A1 (en) * 2020-02-18 2021-08-26 Children's Hospital Medical Center Compositions and methods for treating liver disease
CA3173325A1 (en) * 2020-04-20 2021-10-28 Graham Parry Humanized anti-complement factor bb antibodies and uses thereof

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4866132A (en) 1986-04-17 1989-09-12 The Research Foundation Of State University Of New York Novel radiopaque barium polymer complexes, compositions of matter and articles prepared therefrom
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US5256334A (en) 1988-09-08 1993-10-26 The Research Foundation Of The State University Of New York Homogeneous radiopaque polymer-organobismuth composites
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
DK0648271T3 (da) 1991-08-20 2003-07-21 Us Gov Health & Human Serv Adenovirusmedieret overførsel af gener til mave-/tarmkanal
CA2119930C (en) 1991-09-23 2002-10-01 Hendricus R. J. M. Hoogenboom Production of chimeric antibodies - a combinatorial approach
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
CA2592997A1 (en) 1992-12-03 1994-06-09 Genzyme Corporation Pseudo-adenovirus vectors
US5346981A (en) 1993-01-13 1994-09-13 Miles Inc. Radiopaque polyurethanes
DE614989T1 (de) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.
WO1995000655A1 (en) 1993-06-24 1995-01-05 Mc Master University Adenovirus vectors for gene therapy
ATE314482T1 (de) 1993-10-25 2006-01-15 Canji Inc Rekombinante adenoviren-vektor und verfahren zur verwendung
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
SG165157A1 (en) 1994-12-09 2010-10-28 Emergent Product Dev Uk Ltd Identification of genes
US5939045A (en) 1994-12-22 1999-08-17 Nissan Chemical Industries, Ltd. Organic bismuth derivatives for X-ray imaging
US5670477A (en) 1995-04-20 1997-09-23 Joseph F. Poduslo Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents
DE69731289D1 (de) 1996-03-18 2004-11-25 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
DK0939647T4 (da) 1996-08-27 2006-10-23 Novartis Vaccines & Diagnostic Neisseria Meningitidis-serogruppe B-glycokonjugat og fremgangsmåde til anvendelse deraf
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
EP1040151A4 (en) 1997-12-12 2003-05-21 Macromed Inc HETEROFUNCTIONALIZED STAR POLYETHYLENEGLYCOLS USED TO MODIFY A PROTEIN
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
AU2002248184C1 (en) 2000-12-12 2018-01-04 Board Of Regents, The University Of Texas System Molecules with extended half-lives, compositions and uses thereof
GB0105924D0 (en) 2001-03-09 2001-04-25 Microscience Ltd Promoter
PL1713503T3 (pl) 2004-02-10 2014-02-28 Univ Colorado Regents Hamowanie czynnika B, alternatywny szlak dopełniacza i związane z tym sposoby
CA2568952C (en) 2004-06-18 2019-05-21 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
US20090016959A1 (en) 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
US8741260B2 (en) 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
BRPI0619657A2 (pt) 2005-11-04 2011-11-08 Genentech Inc métodos de prevenção ou melhoria de doença ocular, uso de um inibidor de complemento, uso de um sirna especìfico para uma proteìna do sistema complemento e uso de um ácido nucleico que codifica um inibidor do sistema complemento
PT2913343T (pt) * 2005-12-20 2018-11-21 Sbi Biotech Co Ltd Anticorpo anti-ilt7
CN101970002B (zh) * 2007-08-27 2016-05-18 诺福麦德治疗学股份有限公司 用因子Bb特异性抗体抑制补体活化的方法
AU2008323939A1 (en) * 2007-11-08 2009-05-14 Genentech, Inc. Anti-factor B antibodies and their uses
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
CN103665170A (zh) 2008-12-05 2014-03-26 安吉奥开米公司 肽治疗剂轭合物及其应用
WO2011041391A1 (en) 2009-09-29 2011-04-07 Fraunhofer Usa, Inc. Influenza hemagglutinin antibodies, compositions, and related methods
CA2853719A1 (en) 2011-10-27 2013-05-02 Nkt Therapeutics Inc. Humanized antibodies to inkt
KR20150003169A (ko) 2012-02-24 2015-01-08 스템 센트알엑스 인코포레이티드 Ｄｌｌ3 조절물질들 및 사용 방법
WO2013152020A1 (en) 2012-04-03 2013-10-10 Novelmed Therapeutics, Inc. Humanized and chimeric anti-factor bb antibodies and uses thereof
WO2014044793A2 (en) * 2012-09-20 2014-03-27 Max-Delbrück-Centrum für Molekulare Medizin Cd22-binding peptides
AU2013337638B2 (en) * 2012-11-02 2018-10-25 Recordati Uk Ltd Anti-complement C1s antibodies and uses thereof
PE20151901A1 (es) 2013-02-22 2016-01-13 Abbvie Stemcentrx Llc Nuevos conjugados de anticuerpos y usos de los mismos
US9260527B2 (en) * 2013-03-15 2016-02-16 Sdix, Llc Anti-human CXCR4 antibodies and methods of making same
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
RU2673036C2 (ru) * 2014-02-27 2018-11-21 Аллерган, Инк. АНТИТЕЛА К ФАКТОРУ КОМПЛЕМЕНТА Bb
CN108368170B (zh) 2015-07-13 2022-04-15 西托姆克斯治疗公司 抗pd-1抗体、可活化抗pd-1抗体及其使用方法
SG11201808525UA (en) 2016-04-04 2018-10-30 Bioverativ Usa Inc Anti-complement factor bb antibodies and uses thereof
EP3694874A1 (en) 2017-10-11 2020-08-19 Bioverativ USA Inc. Methods of inducing complement activity
CA3173325A1 (en) 2020-04-20 2021-10-28 Graham Parry Humanized anti-complement factor bb antibodies and uses thereof

Also Published As

Publication number Publication date
CN109563158B (zh) 2022-08-09
KR20190003951A (ko) 2019-01-10
CN116790614A (zh) 2023-09-22
JP2021191789A (ja) 2021-12-16
IL295288A (en) 2022-10-01
TN2018000341A1 (en) 2020-06-15
JP7326393B2 (ja) 2023-08-15
WO2017176651A1 (en) 2017-10-12
ECSP18082302A (es) 2019-01-31
JP2023139289A (ja) 2023-10-03
AU2017246794B2 (en) 2024-07-04
KR20240096672A (ko) 2024-06-26
US20240228599A1 (en) 2024-07-11
AU2024224000A1 (en) 2024-12-19
DOP2018000219A (es) 2019-03-31
IL311675A (en) 2024-05-01
IL262010A (en) 2018-10-31
EP3452510A4 (en) 2020-01-15
MX2018012176A (es) 2019-02-07
MX2023007149A (es) 2023-06-28
US10934347B2 (en) 2021-03-02
IL295288B2 (en) 2024-08-01
AU2017246794A1 (en) 2018-10-25
JP6967528B2 (ja) 2021-11-17
US11851482B2 (en) 2023-12-26
US20210221877A1 (en) 2021-07-22
BR112018070357A2 (pt) 2019-01-29
CA3019332A1 (en) 2017-10-12
CL2018002810A1 (es) 2019-03-15
PH12018502137A1 (en) 2019-09-23
US20190153079A1 (en) 2019-05-23
EA201892225A1 (ru) 2019-09-30
MA44878A (fr) 2019-03-13
CO2018010827A2 (es) 2018-11-22
JP2019513726A (ja) 2019-05-30
KR102673420B1 (ko) 2024-06-07
CR20180529A (es) 2019-03-21
EP3452510A1 (en) 2019-03-13
CN109563158A (zh) 2019-04-02
IL295288B1 (en) 2024-04-01
SG11201808525UA (en) 2018-10-30
IL262010B (en) 2022-09-01
MY194603A (en) 2022-12-06

Similar Documents

Publication Publication Date Title
PE20190209A1 (es) Anticuerpos anti-factor bb del complemento y uso de estos
ECSP19086810A (es) Anticuerpos que se unen específicamente a pd-1 y métodos de uso
CY1123972T1 (el) Θεραπεια συνδυασμου για καρκινο
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
ECSP17063327A (es) Receptores de antígeno quiméricos anti–dll3 y métodos de uso
CO2017005650A2 (es) Anticuerpos anti-interleucina-33
CY1124004T1 (el) Υποδορια σκευασματα αντισωματων αντι-cd38 και οι χρησεις τους
CY1122398T1 (el) Συνδυαστικες θεραπειες με αντισωματα anti-cd38
CY1122721T1 (el) Αντισωματα που δεσμευουν αχl
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
CY1123065T1 (el) Ανασυνδυασμενα προβιοτικα βακτηριδια
EA202092435A2 (ru) Моноклональные антитела против bcma
PE20160690A1 (es) Anticuerpos anti-cd134 (ox40) humanizados y usos de los mismos
EA201791139A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
EA201792467A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
NI201700019A (es) Anticuerpos anti tigit
CY1123290T1 (el) Ενωσεις και μεθοδοι χρησης
PE20161390A1 (es) Anticuerpos multiespecificos
EA201791164A1 (ru) Гетеродимерные антитела, связывающие cd3 и cd38
AR098465A1 (es) ANTICUERPOS ANTI-a-SINUCLEÍNA Y MÉTODOS DE UTILIZACIÓN
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
PE20150002A1 (es) Anticuerpos anti-fcrn
PE20170256A1 (es) Proteinas de union y sus metodos de uso
UY36942A (es) Proteínas de unión a antígeno que activan el receptor de leptina
EA201992091A1 (ru) Анти-c5 антитела и их применение